Chiesi completes acquisition of KalVista for $27 a share

KalVista

KalVista

KALV

0.00
  • Chiesi Group completed its acquisition of KalVista Pharmaceuticals on June 11, 2026.
  • Chiesi’s tender offer paid USD 27 per share in cash, taking about 77.8% of outstanding shares.
  • A follow-on merger cancelled remaining shares, converting them into the same USD 27 per share cash payment.
  • KalVista became a wholly owned Chiesi subsidiary; its Nasdaq-listed stock stopped trading.
  • Chiesi assumed ownership of EKTERLY (sebetralstat), an oral on-demand treatment for hereditary angioedema attacks.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalvista Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260610759093) on June 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.